Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician
Medscape
4 episodes
1 week ago
This series of 4 podcasts will include discussions with expert leaders in melanoma. The content will focus on evaluating the use of immune checkpoint inhibitors in Stage II, Stage III, and Stage IV melanoma, understanding and overcoming resistance to anti- programmed cell death protein 1 (PD-1) immunotherapy, advances in the treatment and outcomes of patients with brain metastases, and the use of adjuvant and neoadjuvant treatment approaches.
All content for Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician is the property of Medscape and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This series of 4 podcasts will include discussions with expert leaders in melanoma. The content will focus on evaluating the use of immune checkpoint inhibitors in Stage II, Stage III, and Stage IV melanoma, understanding and overcoming resistance to anti- programmed cell death protein 1 (PD-1) immunotherapy, advances in the treatment and outcomes of patients with brain metastases, and the use of adjuvant and neoadjuvant treatment approaches.
Understanding and Overcoming Resistance to Anti-PD-1 Immunotherapy in Melanoma
Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician
13 minutes 58 seconds
3 years ago
Understanding and Overcoming Resistance to Anti-PD-1 Immunotherapy in Melanoma
Novel and Emerging Approaches to Melanoma Management: Perspectives for the Community Clinician
This series of 4 podcasts will include discussions with expert leaders in melanoma. The content will focus on evaluating the use of immune checkpoint inhibitors in Stage II, Stage III, and Stage IV melanoma, understanding and overcoming resistance to anti- programmed cell death protein 1 (PD-1) immunotherapy, advances in the treatment and outcomes of patients with brain metastases, and the use of adjuvant and neoadjuvant treatment approaches.
